Combined tetanus-diphtheria and pertussis vaccine during pregnancy: transfer of maternal pertussis antibodies to the newborn

Vilajeliu, Alba; Goncé, Anna; López, Marta; Costa, Josep; Rocamora, Laura; Ríos, José; Teixidó, Irene; Bayas, José M.

doi:10.1016/j.vaccine.2014.12.062

Cited by 76 publications

(51 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…50 Similar findings were reported in studies from Belgium, Israel and Spain, when delivery samples from infants of 57, 61 and 132 Tdap immunized women, respectively, were tested. [70][71][72] The largest reported delivery cohort to date compared infant cord delivery samples from 312 pregnancies where women received Tdap during the third trimester as per CDC recommendations in the US (TdapC) with those from 314 pregnancies where Tdap was not given (Tdap-). 73 The GMC to PT was 47.3 international units (IU)/ml (95% CI 42.1-53.15) in samples from TdapC pregnancies vs. 12.93 IU/ml (95% CI 11.8-14.17) in Tdap-pregnancies (P<0.001).…”

Section: Immune Response Following Pertussis Immunization In Pregnancymentioning

confidence: 99%

“…It is therefore reassuring that data from the larger delivery cohorts estimate that infants of approximately 2 thirds of women receiving Tdap in late pregnancy (20 weeks gestation [Spain]; 27 weeks gestation [US]) would have PT 10 IU/ml at 2 months of age. 72,73 The need for high levels of pertussis antibodies at delivery is important because it influences recommendations on the need for repeated doses of Tdap during subsequent pregnancies and timing of immunization during pregnancy to give maximum immunological benefit to the infant. Recommendations for immunization during every pregnancy in the US were driven by continued high morbidity and mortality in infants, but also by data suggesting that immunization during one pregnancy would be unlikely to protect infants of subsequent pregnancies.…”

Section: Immune Response Following Pertussis Immunization In Pregnancymentioning

confidence: 99%

“…10,74 One study evaluated 105 mother-newborn infant pairs where the mother had received Tdap at a median of 13.4 months (all within 24 months) prior to the birth of the infant. 72 Most mothers had received Tdap postpartum after the birth of a prior infant but 19 received Tdap during pregnancy, 16 in early pregnancy. Although the GMC of pertussis antibodies in maternal and infant cord samples at delivery was higher than that reported in the pre-Tdap era, it was estimated that the GMC of PT-specific IgG would be less than 5 EU/ml in infants by the time of the first DTaP dose and that only 40% of infants would have detectable antibody through age 2 months.…”

Section: Immune Response Following Pertussis Immunization In Pregnancymentioning

confidence: 99%

See 2 more Smart Citations

Pertussis vaccination in pregnancy

Healy

2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Section: Immune Response Following Pertussis Immunization In Pregnancymentioning

confidence: 99%

Section: Immune Response Following Pertussis Immunization In Pregnancymentioning

confidence: 99%

Section: Immune Response Following Pertussis Immunization In Pregnancymentioning

confidence: 99%

See 1 more Smart Citation

Pertussis vaccination in pregnancy

Healy

2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…The concept of maternal immunization is not new and the potential role of whole-cell pertussis containing vaccine (DTwP) in pregnancy was first explored in studies in the early 1940s [8] showing higher levels of antibodies in women with a history of pertussis infection or those immunized during pregnancy with DTwP. Recently, results from PERTU study [9] showed that >94% of infants of 132 mothers who received Tdap vaccination during the late second or third trimester of pregnancy presented levels of anti-pertussis ‡ 10 IU/ml. These findings are consistent with results from other studies [10,11] that have shown that maternal vaccination during pregnancy is associated with significantly higher levels of pertussis antibodies at birth, both in mothers and newborns.…”

mentioning

confidence: 99%

Protecting newborns against pertussis: the value of vaccinating during pregnancy

Vilajeliu

García‐Basteiro

Bayas

2015

Expert Review of Vaccines

Self Cite

View full text Add to dashboard Cite

Resurgence of pertussis has recently been reported in several countries with long-standing pertussis immunization and high vaccination coverage. This situation requires consideration of alternative immunization strategies to protect newborns. In the absence of a vaccine that confers long-lasting immunity, maternal vaccination for pertussis during pregnancy seems to be a safe, immunogenic, effective and accepted strategy to protect infants during the first weeks of life. The existing scientific evidence provides the grounds for pregnant women and healthcare workers to make informed decisions regarding this measure as well as for countries with high pertussis-related infant morbidity and mortality that should consider implementation. Furthermore, this could be a promising strategy to address other vaccine-preventable diseases of pregnancy and the neonatal period.Pertussis is currently a major cause of infant morbidity and mortality worldwide and an emerging public health concern. A resurgence of pertussis cases has recently been reported in several countries with long-standing pertussis immunization and high vaccination coverage such as Spain [1], the USA [2] and the UK [3]. Although the reasons have not been fully elucidated, the improved availability of methods to confirm diagnoses (e.g., PCR), the increased awareness for diagnosis and reporting among health professionals, the different efficacy against disease and infection between whole cell and acellular vaccine, the pathogen adaptation or waning of natural or vaccine immunity during periods of low pertussis activity are thought to play an important role in the current trends of the disease [4]. Neither pertussis natural infection nor vaccination induces lifelong immunity; it has been estimated that only 10% of children will be protected 8.5 years after last dose of Tdap [5]. However, vaccination is the most effective way to combat whooping cough epidemics.Cases increased in several countries in 2011, including high incidence in adulthood. Severe morbidity and mortality from pertussis are concentrated in infants aged <3 months. For example, in 2010, California reported an incidence of 445.9 per 100,000 infants <6 months of age [2], and in 2011, Spain reported an incidence of clinically reported cases higher than 500 cases per 100,000 infants <3 months of age. In the period between 2007 and 2010, there was an increase in infant mortality due to pertussis, being 3.75 deaths per year, compared to 1 death per year in the period 1997-2007 [1]. In UK, 48 deaths in infants under 1 year of age were identified between 2001 and 2011 [3]. In adolescents and adults, pertussis almost always presents as persistent cough, often of undiagnosed cause, and these cases (mainly the parents) are the main sources of infection to susceptible children [1].The current situation requires consideration of alternative immunization strategies to protect newborns. Editorial provided an opportunity of global review of pertussis epidemiology, as well as newly available data on effectiveness...

show abstract

“…9,10 Frequently, this illness appears in the childhood but it can affect at any age. [9][10][11][12][13][14] Pertussis generates high rates of infant morbidity and mortality. It is a health public problem and its epidemic peaks have increased, for that reason, the notification is mandatory.…”

Section: Introductionmentioning

confidence: 99%

Benefits of maternal vaccination to prevent pertussis in infants

Monterrosa-Castro

Ramirez-García

Beltrán-Barrios

2017

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

Pertussis, also called whooping cough, is an infectious and preventable pathology that generates important child morbidity and mortality worldwide. There are different biological preparations for its use in infants, while for adolescents and adults is Tdap, (acellular vaccine of purified extracts of Bordetella pertussis (BP), combined with tetanus and diphtheria toxoid) that has been proposed as maternal vaccination (MV). The objective was to identify the benefits of MV in the prevention of childhood pertussis, a review was made in PubMed, Science Direct, EBSCOhosT, OvidSP and Embase databases (years 2008-2016) and an electronic alert system (January-April 2017). 1083 titles were identified and 44 articles were selected. After the MV (administered between 27 and 36 weeks of gestation) the passage of IgG-BP to the fetus is sufficient to generate adequate infant protection, generating two benefits: reducing infant morbidity (number of cases and hospital admissions) and decreasing mortality by pertussis. The MV offers 93% of effectiveness [95%CI: 81-97] and OR: 0.09 [95%CI: 0,03-0,25]. The MV is more favorable in each pregnancy than cocoon strategy, vaccination before pregnancy, before 26 weeks of gestation or in the postpartum. The use of MV is a safe and cost-effectiveness tool to prevent childhood pertussis.

show abstract

Combined tetanus-diphtheria and pertussis vaccine during pregnancy: transfer of maternal pertussis antibodies to the newborn

Cited by 76 publications

References 30 publications

Pertussis vaccination in pregnancy

Pertussis vaccination in pregnancy

Protecting newborns against pertussis: the value of vaccinating during pregnancy

Benefits of maternal vaccination to prevent pertussis in infants

Contact Info

Product

Resources

About